Behavioral Lifestyle Intervention Study (BLIS) in Patients With Type 2 Diabetes in UAE: A Randomized Controlled Trial in Real Life Setting

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02386930

Enrollment

Registered

2015-03-12

Start date

2013-07-31

Completion date

2014-06-30

Last updated

2015-03-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes

Keywords

Cognitive behavior therapy, Lifestyle modification, HbA1c, Carbohydrates

Brief summary

The primary purpose of this study is to develop a behavioral lifestyle intervention and evaluate its effectiveness in improving the glycemic control in patients with type 2 diabetes in real life setting. This is because ambiguity still exists on the effectiveness of behavioral lifestyle interventions in routine clinical practice despite of the efficacy of large randomized controlled trials, suggesting the need for more research in this area.

Interventions

BEHAVIORALBehvarioal lifestyle modification

A six months behavioral lifestyle program composed of 8 sessions; 4 individual consultations and 4 telephonic calls. The cognitive behavior theory (CBT) is the underpinning theory for the lifestyle intervention; hence CBT behavioral strategies like self monitoring and goal setting are used to improve compliance to healthy lifestyle practices

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Inclusion criteria

Females or males. Type 2 diabetes. BMI (kg/ m²) ≥ 25. Age 18-60 years old. HbA1c \> 7%.

Exclusion criteria

major physical activity disability that restricts participation in moderate physical activity. serious heart condition like heart failure, heart attack, stroke within the last 3 months. participating in a weight management or lifestyle program. presence of proliferative retinopathy or kidney failure.

Design outcomes

Primary

Measure	Time frame
HbA1c%	6 months

Secondary

Measure	Time frame
Body composition analysis	6 months
Lipid profile ( serum cholesterol, LDL, HDL, triglycerides)	6 months
Weight	6 months
carbohydrates intake in grams	6 months
physical exercise in minutes per day	6 months
Blood presssure (systolic and diastolic)	6 months

Countries

United Arab Emirates

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 3, 2026